Literature DB >> 18314464

HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress.

Xenia Moren1, Sara Deakin, Ming-Lin Liu, Marja-Riitta Taskinen, Richard W James.   

Abstract

The subfraction distribution of HDL-associated peptides has implications for their functions and the impact of pathological modifications to lipoprotein metabolism on these functions. We have analyzed the subfraction distribution of paraoxonase-1 (PON1) and the consequences for enzyme activity and stability. HDL subfractions were defined by the presence (LpA-I,A-II) or absence (LpA-I) of apolipoprotein A-II (apoA-II). PON1 was present in both subfractions, although increased concentrations of HDL were associated with significantly increased PON1 in LpA-I. ApoA-II did not modify the capacity of native human HDL or reconstituted HDL to promote PON1 secretion from cells or to stabilize enzyme activity, nor did apoA-II decrease PON1 activity when added to rabbit serum normally devoid of the apolipoprotein. LpA-I,A-II particles isolated from human serum or reconstituted HDL (LpA-I,A-II) showed a significantly greater capacity than HDL(LpA-I) to stabilize secreted PON1 and purified recombinant PON1 added to such particles. PON1 associated with apoA-II-containing particles showed greater resistance to inactivation arising from oxidation. ApoA-I, apoA-II, and LpA-I,A-II, but not LpA-I, were independent determinants of serum PON1 concentration and activity in multivariate analyses. PON1 is at least equally distributed between LpA-I and LpA-II,A-II HDL particles. This dichotomous distribution has implications for PON1 activity and stability that may impact on the physiological role of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18314464     DOI: 10.1194/jlr.M700439-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  10 in total

1.  Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

Authors:  Wilissa D'Souza; John A Stonik; Andrew Murphy; Steven J Demosky; Amar A Sethi; Xiao L Moore; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

Review 2.  Dysfunctional high-density lipoprotein and atherosclerosis.

Authors:  Shawn Ragbir; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

Review 3.  The metabolism and anti-atherogenic properties of HDL.

Authors:  Kerry-Anne Rye; Christina A Bursill; Gilles Lambert; Fatiha Tabet; Philip J Barter
Journal:  J Lipid Res       Date:  2008-11-24       Impact factor: 5.922

4.  In vitro detoxification of cyclosarin in human blood pre-incubated ex vivo with recombinant serum paraoxonases.

Authors:  Yacov Ashani; Moshe Goldsmith; Haim Leader; Israel Silman; Joel L Sussman; Dan S Tawfik
Journal:  Toxicol Lett       Date:  2011-07-23       Impact factor: 4.372

5.  Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment.

Authors:  Judit Marsillach; Gerard Aragonès; Bharti Mackness; Michael Mackness; Anna Rull; Raúl Beltrán-Debón; Juan Pedro-Botet; Carlos Alonso-Villaverde; Jorge Joven; Jordi Camps
Journal:  Lipids Health Dis       Date:  2010-05-14       Impact factor: 3.876

Review 6.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

7.  L-4F inhibits lipopolysaccharide-mediated activation of primary human neutrophils.

Authors:  Oleg F Sharifov; Xin Xu; Amit Gaggar; Edlue M Tabengwa; C Roger White; Mayakonda N Palgunachari; G M Anantharamaiah; Himanshu Gupta
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

8.  Regulation of hepatic paraoxonase-1 expression.

Authors:  Bianca Fuhrman
Journal:  J Lipids       Date:  2012-04-03

9.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17

10.  Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes.

Authors:  Philip W Connelly; Bernard Zinman; Graham F Maguire; Mary Mamakeesick; Stewart B Harris; Robert A Hegele; Ravi Retnakaran; Anthony J G Hanley
Journal:  J Lipid Res       Date:  2009-01-18       Impact factor: 5.922

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.